Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

It is hypothesized that ligand-independent activation of the androgen receptor is one of the mechanisms implicated in tumour progression. However, supportive evidence is limited to the effect of HER-2/neu that stimulates prostate cancer progression through activation of the androgen receptor. In the present study, we have asked whether the proinflammatory cytokine interleukin-6 (IL-6), which is known to stimulate androgen receptor activity and expression of its downstream target genes, may also induce growth of androgen-sensitive cells. We have found that IL-6 differentially regulates proliferation of LAPC-4 and MDA PCa 2b cells. In MDA PCa 2b cells, growth stimulation by IL-6 was reversed by administration of either the non-steroidal anti-androgen bicalutamide or the inhibitor of the mitogen-activated protein kinase pathway PD98059. Neither cell line was found to express endogenous IL-6. Interestingly, the treatment of those prostate cancer cells did not increase phosphorylation of STAT3. The effect of IL-6 on stimulation of androgen receptor activity in MDA PCa 2b cells was lower than that of androgen, comparable with findings reported by other researchers. However, growth of MDA PCa 2b xenografts in castrated animals treated with IL-6 was similar to that in non-castrated animals. In addition, bicalutamide showed an inhibitory effect on IL-6-regulated growth in vivo. Taken together, data in the present study demonstrate that IL-6 may cause growth of androgen receptor-positive tumours in vitro and in vivo through activation of the androgen receptor.

[1]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[2]  C. Tepper,et al.  Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. , 2006, Cancer research.

[3]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[4]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[5]  Jing-Jy Cheng,et al.  Herbal remedy magnolol suppresses IL‐6‐induced STAT3 activation and gene expression in endothelial cells , 2006, British journal of pharmacology.

[6]  A. Papatsoris,et al.  The power and promise of “rewiring” the mitogen-activated protein kinase network in prostate cancer therapeutics , 2007, Molecular Cancer Therapeutics.

[7]  G. Wang,et al.  Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells , 2006, Oncogene.

[8]  G Bartsch,et al.  Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. , 1999, Cancer research.

[9]  J. Bektic,et al.  Regulation of growth of prostate cancer cells selected in the presence of interleukin‐6 by the anti‐interleukin‐6 antibody CNTO 328 , 2006, The Prostate.

[10]  D. Fuchs,et al.  The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1 , 2007, Oncogene.

[11]  M. Oya,et al.  STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. , 2002, Kidney international.

[12]  J. Simons,et al.  Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.

[13]  B. Bonavida,et al.  Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. , 1999, Biochemical and biophysical research communications.

[14]  O. Franco,et al.  Mitogen‐activated protein kinase pathway is involved in androgen‐independent PSA gene expression in LNCaP cells , 2003, The Prostate.

[15]  D. Tindall,et al.  p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.

[16]  F. Fauvel-Lafève,et al.  Stromal cells from human benign prostate hyperplasia produce a growth‐inhibitory factor for LNCaP prostate cancer cells, identified as interleukin‐6 , 1996, International journal of cancer.

[17]  P. Sehgal,et al.  Induction of β 2-interferon by tumor necrosis factor: A homeostatic mechanism in the control of cell proliferation , 1986, Cell.

[18]  D. Fuchs,et al.  Interleukin‐6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase , 2005, The Prostate.

[19]  E. Bissonette,et al.  Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. , 2003, Cancer research.

[20]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[21]  E. Keller,et al.  Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. , 1996, The Journal of biological chemistry.

[22]  C. Sawyers,et al.  NF-κB Activates Prostate-Specific Antigen Expression and Is Upregulated in Androgen-Independent Prostate Cancer , 2002, Molecular and Cellular Biology.

[23]  Taosheng Chen,et al.  Elevation of cyclic adenosine 3',5'-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. , 1999, Cancer research.

[24]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.

[25]  D. Fuchs,et al.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. , 2003, The American journal of pathology.

[26]  Jin-Tang Dong.  Prevalent mutations in prostate cancer , 2006, Journal of cellular biochemistry.

[27]  S. Rudikoff,et al.  IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells , 2002, Oncogene.

[28]  A. Dunn,et al.  gp130-mediated Signal Transduction in Embryonic Stem Cells Involves Activation of Jak and Ras/Mitogen-activated Protein Kinase Pathways* , 1996, The Journal of Biological Chemistry.

[29]  Hideo Araki,et al.  Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. , 2003, Cancer research.

[30]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[31]  A. Nel,et al.  Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line, AF-10. , 1993, Journal of immunology.

[32]  A. J. Garrett,et al.  CANCER XENOGRAFTS IN NUDE MICE , 1976, The Lancet.

[33]  C. Sawyers,et al.  NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. , 2002, Molecular and cellular biology.

[34]  H. Kung,et al.  Neuropeptide-Induced Androgen Independence in Prostate Cancer Cells: Roles of Nonreceptor Tyrosine Kinases Etk/Bmx, Src, and Focal Adhesion Kinase , 2001, Molecular and Cellular Biology.

[35]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[36]  D. Peehl,et al.  Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. , 1999, The Journal of urology.

[37]  Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and low-affinity NGF receptors. , 2000, Molecular endocrinology.

[38]  E. Keller,et al.  Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice , 2001, The Prostate.

[39]  Brooks Pm,et al.  Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. , 1993 .

[40]  W. Farrar,et al.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.

[41]  N. Bruchovsky,et al.  Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.

[42]  M. Morimatsu,et al.  Central IL-1 differentially regulates peripheral IL-6 and TNF synthesis , 1998, Cellular and Molecular Life Sciences CMLS.

[43]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Z. Hall.  Cancer , 1906, The Hospital.

[45]  W. Isaacs,et al.  ras gene mutations in human prostate cancer. , 1990, Cancer research.

[46]  D. Johnston,et al.  Establishment of two human prostate cancer cell lines derived from a single bone metastasis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  H. Scher,et al.  Collocation of androgen receptor gene mutations in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  P. Brooks,et al.  Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. , 1993, Clinical and experimental rheumatology.

[49]  Chawnshang Chang,et al.  Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. , 2003, Biochemical and biophysical research communications.

[50]  P. Heinrich,et al.  Cell Density–Dependent Increase of Constitutive Signal Transducers and Activators of Transcription 3 Activity in Melanoma Cells Is Mediated by Janus Kinases , 2007, Molecular Cancer Research.

[51]  Yi Lu,et al.  Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. , 2006, Cancer research.

[52]  L. Koniaris,et al.  Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. , 2008, The Journal of surgical research.

[53]  Nicholas Bruchovsky,et al.  Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[54]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[55]  Chawnshang Chang,et al.  Inhibition of NFκB Activity through Maintenance of IκBα Levels Contributes to Dihydrotestosterone-mediated Repression of the Interleukin-6 Promoter* , 1996, The Journal of Biological Chemistry.

[56]  H. Klocker,et al.  Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  P. Johnston,et al.  Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. , 2008, Carcinogenesis.

[58]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[59]  M. Nakafuku,et al.  Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active Ras.GTP complex in rat pheochromocytoma PC12 cells. , 1992, The Journal of biological chemistry.

[60]  M. Kuo,et al.  Interleukin-6 Inhibits Transforming Growth Factor-β-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Akt and Signal Transducers and Activators of Transcription 3 Pathways* , 1999, The Journal of Biological Chemistry.

[61]  B. Wegiel,et al.  Interleukin‐6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival , 2007, International journal of cancer.

[62]  J. Pinski,et al.  Interleukin‐6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation , 2004, International journal of cancer.

[63]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[64]  G. Bartsch,et al.  Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. , 2005, Endocrine-related cancer.

[65]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[66]  H. Broxmeyer,et al.  Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. , 1995, The Journal of clinical investigation.

[67]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[68]  Y. Horiguchi,et al.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[70]  T. Chung,et al.  STAT3 mediates IL‐6‐induced growth inhibition in the human prostate cancer cell line LNCaP , 2000, The Prostate.

[71]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[72]  G. Bartsch,et al.  Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. , 2006, The American journal of pathology.